Ideaya Biosciences

Yahoo Finance • last month

10 most overbought S&P 500 stocks ahead of PPI and CPI data

[Top 10 alphabet letters top view on purple glitter background] Wall Street has started the week on a cautious tone as investors flag the most overbought stocks in the S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]), while broader... Full story

Yahoo Finance • last month

KNDS CEO is said to see 2026 IPO as 'realistic' path to expansion

[German tanks Leopard 2 parked on a street] Tramino KNDS, the Franco-German tankmaker behind the Leopard 2, is laying the groundwork for a potential initial public offering in 2026 as it looks to broaden its shareholder base and finance g... Full story

Yahoo Finance • last month

Biggest stock movers Monday: RAPP, HOUR, IDYA, NFE and more

[Shot of a handsome young businessman using a digital tablet while working late in his office] PeopleImages U.S. stock futures edged up on Monday as investors looked ahead to two important inflation reports this week, that will shape expe... Full story

Yahoo Finance • last month

Ideaya Biosciences gets coverage initiation at Barclays and Citizens

[Wall Street sign, New York City, USA] mbbirdy/E+ via Getty Images Ideaya Biosciences (NASDAQ:IDYA [https://seekingalpha.com/symbol/IDYA]) got coverage initiation from Barclays and Citizens, reflecting increasing confidence in the company... Full story

Yahoo Finance • last month

IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., Sept. 4, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have enrolled their first patient with non-small cell lung cancer (NSCL... Full story

Yahoo Finance • last month

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on August... Full story

Yahoo Finance • 2 months ago

IDEAYA Biosciences announces agenda for upcoming R&D day

NEW YORK - IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine company with a market capitalization of $2.1 billion that maintains a strong balance sheet with more cash than debt, has announced the agenda for its upcoming Research... Full story

Yahoo Finance • 2 months ago

Ideaya Biosciences earnings missed by $0.09, revenue topped estimates

Investing.com - Ideaya Biosciences (NASDAQ: IDYA) reported second quarter EPS of $-0.88, $0.09 worse than the analyst estimate of $-0.79. Revenue for the quarter came in at $6M versus the consensus estimate of $3.81M. Ideaya Biosciences’s... Full story

Yahoo Finance • 3 months ago

Bullish Two Hundred Day Moving Average Cross - IDYA

In trading on Wednesday, shares of IDEAYA Biosciences Inc (Symbol: IDYA) crossed above their 200 day moving average of $22.89, changing hands as high as $23.36 per share. IDEAYA Biosciences Inc shares are currently trading up about 5.5% o... Full story

Yahoo Finance • 3 months ago

IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy

SOUTH SAN FRANCISCO, Calif., July 23, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it will host an in-per... Full story

Yahoo Finance • 3 months ago

Hengrui to present phase 1 data on DLL3-targeting lung cancer drug

JIANGSU, China - IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a $1.9 billion market cap biotech company with a robust balance sheet showing more cash than debt, and Jiangsu Hengrui Pharmaceuticals announced Tuesday that clinical data for their... Full story

Yahoo Finance • 3 months ago

Ideaya Biosciences stock price target lowered to $30 by RBC Capital

Investing.com - RBC Capital lowered its price target on Ideaya Biosciences (NASDAQ:IDYA) to $30.00 from $57.00 on Wednesday, while maintaining an Outperform rating on the biopharmaceutical company. The stock, currently trading at $22.42, h... Full story

Yahoo Finance • 9 months ago

IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in t... Full story

Yahoo Finance • last year

IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study

Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024, at 9:51 AM CDT The abstract summary will be available on Thursday, May 23, 2024 at ~5:00pm ET SOUTH SAN FRANCISCO, Calif., April 24, 2024 /PRNewswire/ -- IDEAYA Bioscience... Full story

Yahoo Finance • 2 years ago

IDEAYA Biosciences Inc CEO Yujiro Hata Sells 99,372 Shares

On February 9, 2024, Yujiro Hata, the President and CEO of IDEAYA Biosciences Inc (NASDAQ:IDYA), sold 99,372 shares of the company. The transaction was reported in a SEC Filing. Following this transaction, the insider's total sales over th... Full story

Yahoo Finance • 2 years ago

IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

Strong balance sheet of $511.1 million of cash, cash equivalents and marketable securities as of September 30, 2023, supplemented by $134.7 million estimated net proceeds from subsequent follow-on financing and $10.0 million receivable fro... Full story

Yahoo Finance • 2 years ago

Investors in IDEAYA Biosciences (NASDAQ:IDYA) have seen impressive returns of 223% over the past three years

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But if you buy shares in a really great company, you can more than double your money. For instance the IDEAYA Bioscie... Full story

Yahoo Finance • 3 years ago

IDEAYA Biosciences to Participate in the 2023 Guggenheim Oncology Conference

SOUTH SAN FRANCISCO, Calif., Feb. 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, annou... Full story

Yahoo Finance • 3 years ago

IDEAYA Announces IND Clearance by U.S. FDA enabling Phase 1 Initiation for First-in-Class PARG Development Candidate IDE161

- Targeting to initiate dosing of Phase 1 clinical trial in Q1 2023 to evaluate IDE161 in patients having tumors with HRD, including BRCA1/2-mutant breast and ovarian cancer - Starting dose of IDE161 in the Phase 1 dose escalation is one-... Full story

Yahoo Finance • 3 years ago

IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-Deletion Tumors

­First patient dosed in IDE397 combination with pemetrexed, representing a novel and potential first-in-class combination in MTAP-deletion tumors First patient dosed in IDE397 combination with taxane in MTAP-deletion tumors Clinical strate... Full story